Vogt–Koyanagi–Harada disease Vogt–Koyanagi–Harada disease Vogt–Koyanagi–Harada disease (VKH), also known as Vogt–Koyanagi–Harada syndrome, uveomeningitis syndrome and uveomeningoencephalitic syndrome, is a multisystem disease of presumed autoimmune cause, that affects pigmented tissues, which have melanin. The most significant manifestation is bilateral, diffuse uveitis, which affects the eye. VKH may variably also involve the inner ear with effects on hearing, the skin, and the meninges of the central nervous system. The disease is characterised by bilateral diffuse uveitis, with pain, redness and blurring of vision. The eye symptoms may be accompanied by a varying constellation of systemic symptoms, such as auditory (tinnitus, vertigo, and hypoacusis), neurological
Tinnitus masker for hearing loss. Sound generators (masking devices) have received Class II approval from the FDA. However, they are considered to be “experimental, investigational, or unproven” therapies. There is one report of a bone conduction vibration masker that transmits a 60 Hz fundamental with adjustable harmonics up to 1000 Hz. A commercial device based on the phenomenon (Aurex3) was approved by the FDA. A new development in tinnitus management is the use of high audio (10 kHz-20 kHz) or ultrasonic (20-100 kHz) via bone conduction. A 2012 Cochrane Review stated the available studies do not show strong evidence of the efficacy